Multisystem thromboembolism in a COVID-19 patient: a case report

Abstract

Hypercoagulability has been found in patients diagnosed with the novel coronavirus 19 (COVID-19) and has been identified as a major cause of morbidity and mortality. Herein, we report the challenge in managing a patient presenting with a 5 day history of COVID-19 diagnosis, complicated by deep venous thrombosis, pulmonary embolism and ischemic stroke in the setting of atrial septal aneurysm, presumed patent foramen ovale and paradoxical embolism, identified to have clots in transit on echocardiogram. The application of anticoagulation was felt to be high risk. The patient was transferred to a tertiary facility where the patient underwent thrombus aspiration and was eventually complicated by hemorrhagic conversion of the stroke.

Imaging findings of two patients with isolated infarction of the splenium during COVID-19

“… 10 Hypercoagulable events have been reported in around 50% of cases with severe COVID-19. 11 Venous thromboembolism seems to be more frequently encountered as a thromboembolic complication of this disease, compared with arterial thrombosis. 12 To date, the real prevalence of thromboembolic complications of COVID-19 remains unknown, and much more investigations are needed to provide and gather patient data and analyze them with systematic and comprehensive methods.…”